CoChat

Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation

Qu, Xinli, Zhang, Xueming, Yao, Jun, Song, Jiangning, Nikolic‐Paterson, David J, Li, Jinhua · 2012 · The Journal of Pathology
Cited by 107

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Resolvin E1 (RvE1) is a naturally occurring lipid‐derived mediator generated during the resolution of inflammation. The anti‐inflammatory effects of RvE1 have been demonstrated in a variety of disease settings; however, it is not known whether RvE1 may also exert direct anti‐fibrotic effects. We examined the potential anti‐fibrotic actions of RvE1 in the mouse obstructed kidney—a model in which tissue fibrosis is driven by unilateral ureteric obstruction (UUO), an irreversible, non‐immune insult. Administration of RvE1 (300 ng/day) to mice significantly reduced accumulation of α‐smooth muscle actin (SMA)+ myofibroblasts and the deposition of collagen IV on day 6 after UUO. This protective effect was associated with a marked reduction of myofibroblast proliferation on days 2, 4 and 6 after UUO. RvE1 treatment also inhibited production of the major fibroblast mitogen, platelet‐derived growth factor‐BB (PDGF‐BB), in the obstructed kidney. Acute resolvin treatment over days 2–4 after UUO also had a profound inhibitory effect upon myofibroblast proliferation without affecting the PDGF expression, suggesting a direct effect upon fibroblast proliferation. In vitro studies established that RvE1 can directly inhibit PDGF‐BB‐induced proliferation in primary mouse fibroblasts. RvE1 induced transient, but not sustained, activation of the pro‐proliferative ERK and AKT signalling pathways. Of note, RvE1 inhibited the sustained activation of ERK and AKT pathways seen in response to PDGF stimulation, thereby preventing up‐regulation of molecules required for progression through the cell cycle (c‐Myc, cyclin D) and down‐regulation of inhibitors of cell cycle progression (p21, cip1). Finally, siRNA‐based knock‐down studies showed that the RvE1 receptor, ChemR23, is required for the anti‐proliferative actions of RvE1 in cultured fibroblasts. In conclusion, this study demonstrates that RvE1 can inhibit fibroblast proliferation in vivo and in vitro, identifying RvE1 as a novel anti‐fibrotic therapy. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.4050

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 107

Metadata

Authors
Qu, X., Zhang, X., Yao, J., Song, J., Nikolic‐Paterson, D. J., & Li, J.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2012-11-06
Volume
228
Issue
4
Pages
506-519
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W1516619259
Cited by
107
References
6
FWCI
6.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.